The drug can’t do its job if patients can’t take it

The patient experience matters when it comes to how a drug is delivered. If an API leaves a bitter or otherwise unpleasant taste in the mouth, patients may reject the product leading healthcare providers to look for alternatives. Tastemasking can solve this problem. Combined with flavors and sweeteners, tastemasking can transform a problematic API into a preferred product.

CIMA understands the complex relationship between a drug’s physicochemical properties and its taste. CIMA taste-masking technologies can be utilized with OraSolv, DuraSolv, Lyoc and oral granules and powders.

Balancing physicochemical drug properties and taste

CIMA has successfully applied taste-masking techniques to drug molecules ranging from     0.1 mg to 750 mg in dose, independent of solubility. In addition, CIMA has overcome technical challenges of compounds that are needle-shaped, micronized, reactive or hydrate-forming. These may also be formulated with immediate or customized release profiles.

When taste-masking a drug, it’s important to strike a balance between dissolution and the organoleptic properties of the finished product. To accomplish this, selecting and optimizing coating excipients and their process is essential.

CIMA uses polymers such as celluloses (EC, HPMC, etc.) to moderate dissolution independent of pH, and methacrylates (EUDRAGIT®), which exhibit pH-dependent dissolution. Depending on the characteristics of the drug, a variety of taste-masking and particle coating processes may be employed. Examples include solution layering, wet and/or dry granulation, suspension layering, alcoholic or hydro-alcoholic solution layering, and direct coating. Fluid-bed particle coating (Wurster) is used for the majority of these processes.

Successfully taste-masking drug products

Patients prefer the convenience of orally disintegrating tablets. Consider Orapred ODT®. In an ongoing patient survey with more than 900 responses:

  • 89% of patients prefer Orapred ODT® to a liquid steroid
  • 96% of patients complied with the prescribed regimen

Reference: Patient Feedback Survey. Data on file as of 03/23/07. Alliant Pharmaceuticals, Inc. (now Sciele Pharma, Inc.)



Orapred ODT® is a registered trademark of BioMarin.

Overview

The drug can’t do its job if patients can’t take it

The patient experience matters when it comes to how a drug is delivered. If an API leaves a bitter or otherwise unpleasant taste in the mouth, patients may reject the product leading healthcare providers to look for alternatives. Tastemasking can solve this problem. Combined with flavors and sweeteners, tastemasking can transform a problematic API into a preferred product.

CIMA understands the complex relationship between a drug’s physicochemical properties and its taste. CIMA taste-masking technologies can be utilized with OraSolv, DuraSolv, Lyoc and oral granules and powders.

Technical Notes

Balancing physicochemical drug properties and taste

CIMA has successfully applied taste-masking techniques to drug molecules ranging from     0.1 mg to 750 mg in dose, independent of solubility. In addition, CIMA has overcome technical challenges of compounds that are needle-shaped, micronized, reactive or hydrate-forming. These may also be formulated with immediate or customized release profiles.

When taste-masking a drug, it’s important to strike a balance between dissolution and the organoleptic properties of the finished product. To accomplish this, selecting and optimizing coating excipients and their process is essential.

CIMA uses polymers such as celluloses (EC, HPMC, etc.) to moderate dissolution independent of pH, and methacrylates (EUDRAGIT®), which exhibit pH-dependent dissolution. Depending on the characteristics of the drug, a variety of taste-masking and particle coating processes may be employed. Examples include solution layering, wet and/or dry granulation, suspension layering, alcoholic or hydro-alcoholic solution layering, and direct coating. Fluid-bed particle coating (Wurster) is used for the majority of these processes.

Case Study

Successfully taste-masking drug products

Patients prefer the convenience of orally disintegrating tablets. Consider Orapred ODT®. In an ongoing patient survey with more than 900 responses:

  • 89% of patients prefer Orapred ODT® to a liquid steroid
  • 96% of patients complied with the prescribed regimen

Reference: Patient Feedback Survey. Data on file as of 03/23/07. Alliant Pharmaceuticals, Inc. (now Sciele Pharma, Inc.)



Orapred ODT® is a registered trademark of BioMarin.